18F-Fluoride Imaging: Monitoring Therapy
Novel oncologic therapeutic agents, whether chemotherapy, hormone therapy, immunotherapy, or radiotracers such as 223Ra and 177Lu-PSMA are expensive and diagnostic test able to predict and monitor response to treatment, avoid overtreatment and unnecessary
- PDF / 6,631,729 Bytes
- 107 Pages / 439.42 x 666.14 pts Page_size
- 115 Downloads / 180 Views
evi Kairemo Homer A. Macapinlac Editors
Sodium Fluoride PET/ CT in Clinical Use
Clinicians’ Guides to Radionuclide Hybrid Imaging PET/CT
Series Editors Jamshed B. Bomanji London, UK Gopinath Gnanasegaran London, UK Stefano Fanti Bologna, Italy Homer A. Macapinlac Houston, Texas, USA
More information about this series at http://www.springer.com/series/13803
Kalevi Kairemo • Homer A. Macapinlac Editors
Sodium Fluoride PET/CT in Clinical Use
Editors Kalevi Kairemo Department of Nuclear Medicine University of Texas MD Anderson Cancer Center Houston, TX USA
Homer A. Macapinlac Department of Nuclear Medicine University of Texas MD Anderson Cancer Center Houston, TX USA
ISSN 2367-2439 ISSN 2367-2447 (electronic) Clinicians’ Guides to Radionuclide Hybrid Imaging - PET/CT ISBN 978-3-030-23576-5 ISBN 978-3-030-23577-2 (eBook) https://doi.org/10.1007/978-3-030-23577-2 © Springer Nature Switzerland AG 2020 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors, and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, expressed or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. This Springer imprint is published by the registered company Springer Nature Switzerland AG The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland
PET/CT series is dedicated to Prof Ignac Fogelman, Dr Muriel Buxton-Thomas and Prof Ajit K Padhy
Foreword
Clear and concise clinical indications for PET/CT in the management of the oncology and non-oncology patient are presented in this series of 15 separate booklets. The impact on better staging, tailored management and specific treatment of the patient with cancer has been achieved with the advent of this multimodality imaging technology. Early and accurate diagnosis will always pay, and clear information can be gathered with PET/CT on treatment responses. Prognostic information is gathered and can forward guide additional therapeutic options. It is a fortunate coincidence that PET/CT was able to derive great benefit from radio
Data Loading...
